Melanoma

Open Clinical Trials

Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab

Protocol Number: Alliance EA6134
A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma – OPEN TO ENROLLMENT

Dabrafenib, Trametinib, Ipilimumab Nivolumab

Protocol Number: ALLIANCE EA6134
A Randomized Phase 3 Trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma – OPEN TO ENROLLMENT